A subsidiary of India's largest pharmaceutical company has agreed to pay a record $500 million in fines and penalties for selling adulterated drugs and lying to federal regulators in a case that is part of an ongoing crackdown on the quality of generic drugs flowing into the U.S.
[More]
Today's headlines include reports about an Obama administration plan to delay Medicaid DSH payment reductions.
[More]
Akorn, Inc., a niche generic pharmaceutical company, today reported financial results for its first quarter ended March 31, 2013.
[More]
IGI Laboratories, Inc., a New Jersey based topical generic drug development and manufacturing company, announced its financial results for the first quarter ended March 31, 2013.
[More]
Teva Pharmaceutical Industries Ltd. and Xenon Pharmaceuticals Inc. announced today that the US Food and Drug Administration has granted orphan-drug designation to the investigational drug XEN402 being developed for the treatment of pain associated with erythromelalgia.
[More]
BD Rx Inc., a wholly-owned subsidiary of leading global medical technology company BD, announced today that the U.S. Food and Drug Administration has approved the second drug to be offered in the recently launched BD Simplist line of ready-to-administer prefilled generic injectables.
[More]
Today's headlines include reports from Capitol Hill about one Democratic senator's poor reviews of the Obama administration's progress in implementing the health law.
[More]
Teva Pharmaceutical Industries Ltd. today presented data from a sub-analysis of a Phase III clinical trial of Milprosa (progesterone) vaginal ring, an investigational, once-weekly therapy for luteal phase support in women undergoing in vitro fertilization.
[More]
A laboratory study has shown for the first time that coenzyme Q10 offsets the cellular changes that are linked to a side-effect of some statin drugs - an increased risk of adult-onset diabetes.
[More]
The preclinical contract research organization Absorption Systems, a global leader in pharmacokinetic testing of drugs, announces that it has entered into a partnership with the Indian pharmaceutical consulting firm Synerzys Lifecare Pvt Ltd.
[More]
"In a decisive victory for India's pharmaceutical industry, India's Supreme Court rejected Novartis' patent application for the cancer drug Glivec on Monday, ending a seven-year battle by the Swiss drug maker to get a patent in India on its powerful leukemia drug," Time reports (Mahr, 4/1).
[More]
"India's Supreme Court on Monday rejected drug maker Novartis AG's attempt to patent an updated version of a cancer drug in a landmark decision that health activists say ensures poor patients around the world will get continued access to cheap versions of lifesaving medicines," the Associated Press reports.
[More]
Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration has approved Quartette (levonorgestrel/ethinyl estradiol and ethinyl estradiol) tablets for the prevention of pregnancy.
[More]
The U.S. government's fiscal predicament has many causes. But if you had to reduce them to one sentence, it might go like this: "Congress responds to the short-term demands of particular groups, not the long-term needs of the nation as a whole."
[More]
The Supreme Court heard arguments yesterday in a case which pits brand name and generic drug manufacturers against the Federal Trade Commission.
[More]
Generic and the brand-name drug companies -- usually fierce competitors -- will be on the same side as they argue their case against the federal government.
[More]
Today's headlines include reports about the continuing outlook for progress on the federal budget as well as a variety of stories related to the health law's implementation.
[More]
The Supreme Court is weighing if generic drugmakers can be sued over the safety of their drugs or if federal regulators' safety approval is enough to block all such legal challenges.
[More]
Ben-Gurion University of the Negev researchers, in collaboration with Teva Pharmaceutical Industries Ltd., have developed a promising drug candidate to treat psoriasis.
[More]
Today's headlines include reports about how the health law's insurance expansion could cause stress among health care providers and strain within the health system.
[More]